The field of synthetic biology has hit a wall that looks suspiciously familiar to anyone tracking AI safety: we can build complex systems, but we struggle to understand why they actually work. Fewer than 10% of drugs that enter clinical trials ultimately reach patients, and billions of dollars vanish annually on preclinical programs that fail to produce actionable insights. According to Krish Ramadurai, a Partner at AIX Ventures and Oxford-trained biomolecular engineer, this crisis isn't a separate problem from synthetic biology's core challenge. It's a symptom of the same underlying constraint: the inability to open the biological black box .

What Is the Biological Black Box Problem?

DNA can now be designed and written with remarkable ease. The hard part is understanding why that DNA behaves the way it does once it enters a living system. Ramadurai frames this as the central tension in modern synthetic biology. "We could design sequences, but we couldn't reliably predict how they would behave in complex biological systems," he explained. This gap between design capability and predictive understanding has become the field's defining constraint .

The problem manifests in concrete ways. Researchers can engineer cells to sense, compute, or manufacture molecules, but when those constructs enter the messy reality of a living organism, outcomes become unpredictable. The translatability crisis, where promising lab results fail to translate into clinical success, isn't a separate issue. It's a direct consequence of not understanding the mechanistic reasons why a biological construct behaves as it does .

How Can Mechanistic AI Help Biology Become More Interpretable?

Ramadurai's investment thesis centers on a specific solution: mechanistic AI and multimodal systems that generate causal rules rather than correlations. Unlike traditional machine learning models that identify statistical patterns, mechanistic approaches aim to uncover the actual mechanisms driving biological behavior. This shift matters because it transforms biology from a black box into something closer to a coding problem, where each component's function can be understood and predicted .

The founders Ramadurai is backing in 2026 are working on what he calls "Black Box to Blueprint" initiatives. These are platforms designed to make interpretability a core design criterion from the start, not an afterthought. The practical implication is significant: instead of running experiments that produce data endpoints, researchers would design workflows that generate interpretable signals at each step .

Steps for Building More Interpretable Biological Systems

• Design mechanistically faithful models: Build physiologically relevant model systems that better bridge the gap between petri dish experiments and patient outcomes, ensuring predictions translate to real-world biology.
• Generate interpretable signals: Design experiments that produce clear, explainable outputs rather than just raw data endpoints, making each result actionable rather than opaque.
• Embed explainability into workflows: Integrate interpretability directly into automated experimental pipelines so that each iteration produces insight alongside data, creating a feedback loop of understanding.

Ramadurai's message to synthetic biologists is concrete and actionable. The next generation of platforms will win by being both mechanistic and measurable. "Interpretability is the new scalability," he stated, emphasizing that understanding how systems work is becoming as important as scaling their production .

"For the first time in human history, we can actually engineer biology from a first-principles basis using AI and begin to turn biology into a coding problem," said Krish Ramadurai.

Krish Ramadurai, Partner at AIX Ventures

Why This Matters Beyond the Lab

The connection between AI interpretability and biological interpretability reveals something important about complex systems generally. When you can't explain why a system produces a particular output, you can't reliably improve it, scale it, or trust it in high-stakes applications. In AI, this has driven the entire field of mechanistic interpretability research. In biology, it's now driving investment decisions .

Ramadurai's career trajectory reflects this insight. He trained at Harvard's Belfer Center under former U.S. Secretary of Defense Ash Carter and Nobel Laureate Michael Kremer, and at Oxford's Institute of Biomedical Engineering, where he focused on multimodal AI simulation frameworks for drug development. Across more than 50 investments spanning healthcare and life sciences, including companies like Insilico Medicine, bit.bio, and Volumetric Biotechnologies, his work has been driven by a single conviction: understanding must scale faster than data generation .

The message is aimed at builders, founders, researchers, and operators working to make biology more predictable. The foundations for opening the biological black box are beginning to emerge, and the next wave of techbio founders will be those who make biological complexity interpretable, predictable, and investable. This shift from pure data generation to mechanistic understanding represents a fundamental reorientation of how the field approaches the design and validation of biological systems .